Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPA-15406 foam in adult atopic dermatitis
NCT07173478Phase 3Not yet recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing 1% OPA-15406 foam with Vehicle (2 arms). Primary endpoint: Success rate in Investigator's Global Assessment (IGA) at 4 weeks. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
difamilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07173478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07173478.